BRIEF — ThromboGenics to change name

Belgian ophthalmology company ThromboGenics is to change its name to Oxurion.

Subject to the approval of the shareholders’ assembly, the name change will become effective in the week commencing September 10, 2018. The name change will also result in the company’s stock ticker symbol changing from THR to OXUR.

Patrik De Haes, chief executive of ThromboGenics, said: “The new name, Oxurion, is designed to better reflect our ambition to deliver best in class therapies for back of the eye disorders. The renaming comes at a moment when we have reached important clinical milestones and are accelerating the execution of our unique pipeline of disease modifying compounds for diabetic eye disease. Moreover, we are also looking at expanding our drug development efforts into additional and new areas of back of the eye disease.”

The name Oxurion is derived from a combination of oxygen and Orion, a Greek mythological figure who, after being blinded, had his vision restored by Helios, the God of the Sun.